Northwest & Ethical Investments L.P. Has $574,000 Holdings in Bausch Health Companies Inc. (NYSE:BHC)

Northwest & Ethical Investments L.P. increased its stake in Bausch Health Companies Inc. (NYSE:BHC - Free Report) by 119.7% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 71,139 shares of the company's stock after purchasing an additional 38,755 shares during the quarter. Northwest & Ethical Investments L.P.'s holdings in Bausch Health Companies were worth $574,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of BHC. Goldentree Asset Management LP raised its position in shares of Bausch Health Companies by 31.0% during the 3rd quarter. Goldentree Asset Management LP now owns 29,395,745 shares of the company's stock worth $239,552,000 after buying an additional 6,958,717 shares in the last quarter. Bank of Montreal Can raised its holdings in Bausch Health Companies by 234.0% during the third quarter. Bank of Montreal Can now owns 3,833,179 shares of the company's stock worth $31,598,000 after purchasing an additional 2,685,675 shares in the last quarter. Maple Rock Capital Partners Inc. acquired a new stake in Bausch Health Companies in the third quarter worth approximately $16,850,000. SG Americas Securities LLC boosted its stake in Bausch Health Companies by 62.0% during the 4th quarter. SG Americas Securities LLC now owns 3,301,981 shares of the company's stock valued at $26,614,000 after purchasing an additional 1,263,706 shares in the last quarter. Finally, Readystate Asset Management LP increased its position in shares of Bausch Health Companies by 38.1% during the 3rd quarter. Readystate Asset Management LP now owns 470,761 shares of the company's stock valued at $3,841,000 after purchasing an additional 130,000 shares during the period. Institutional investors own 78.65% of the company's stock.

Remove Ads

Bausch Health Companies Stock Down 3.3 %

Shares of NYSE BHC traded down $0.24 during mid-day trading on Tuesday, hitting $7.03. 2,220,648 shares of the company traded hands, compared to its average volume of 2,711,104. The business has a 50 day moving average of $7.12 and a two-hundred day moving average of $7.72. The stock has a market capitalization of $2.59 billion, a price-to-earnings ratio of -58.58, a PEG ratio of 0.37 and a beta of 0.59. Bausch Health Companies Inc. has a 1 year low of $3.96 and a 1 year high of $11.46.

Bausch Health Companies (NYSE:BHC - Get Free Report) last posted its quarterly earnings data on Wednesday, February 19th. The company reported $1.21 EPS for the quarter, missing analysts' consensus estimates of $1.65 by ($0.44). The firm had revenue of $2.56 billion for the quarter, compared to analysts' expectations of $2.51 billion. Bausch Health Companies had a negative net margin of 0.48% and a negative return on equity of 577.82%. As a group, research analysts anticipate that Bausch Health Companies Inc. will post 4.41 EPS for the current year.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on BHC. Royal Bank of Canada cut their price objective on Bausch Health Companies from $11.00 to $10.00 and set a "sector perform" rating for the company in a report on Thursday, January 30th. Jefferies Financial Group reissued a "hold" rating and issued a $8.00 price target (down from $12.00) on shares of Bausch Health Companies in a report on Thursday, February 6th. One equities research analyst has rated the stock with a sell rating, six have given a hold rating and one has issued a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Hold" and a consensus target price of $7.42.

About Bausch Health Companies

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.